@entity136 -induced peripheral XXXX : report on 15 cases and review of the literature.

@entity1 @entity4 @entity1150 @entity74 @entity136 @entity288
Some degree of peripheral @entity4 occurs in up to 20% of @entity1 treated with @entity136 (Gemzar). The @entity4 is typically mild, requiring discontinuation of the drug in less than 1% of @entity1 . Most @entity1 require no therapy. However, in cases of peripheral @entity4 , grade II or higher, suspension of @entity136 and treatment with @entity288 are often necessary, and permanent discontinuation of @entity136 may be required on occasion. We have identified 15 cases of peripheral @entity4 , grade II or greater, developing in @entity1 receiving @entity136 chemotherapy at Memorial Sloan-Kettering Cancer Center. The diagnosis was made based on temporal association with drug administration, and exclusion of other potential acute causes of @entity4 including @entity74 and @entity1150 . The 15 @entity1 in this series represent less than 1% of all @entity1 treated with @entity136 at this institution over the same time period. @entity136 was immediately discontinued at the time of the onset of @entity4 in 7 of the 15 @entity1 due to severity of the symptoms. Thirteen of the 15 @entity1 in this case series had experienced peripheral @entity4 previously, and 6 had active low-grade @entity4 at the time the @entity136 was first administered. @entity1 receiving @entity136 should be advised of this potential complication and urged to promptly report its development so that comorbid conditions can be excluded and proper supportive measures initiated. @entity1 predisposed to peripheral @entity4 from some other cause may be at increased risk for developing severe peripheral @entity4 with @entity136 .
